{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:46:45Z","timestamp":1785775605913,"version":"3.56.0"},"reference-count":22,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urol Int"],"abstract":"<jats:p>Introduction: Persistent lower urinary tract symptoms (LUTSs) in young adults following childhood primary nocturnal enuresis (PNE) refractory to desmopressin represent an undercharacterized condition at the pediatric-adult care interface. No prior study has compared pharmacotherapy options in this specific population. Methods: We performed a retrospective, single-center, hypothesis-generating comparative cohort study at a tertiary urology center (January 2017\u2013September 2025). Male adults aged 18\u201335 years with documented childhood PNE based on International Children\u2019s Continence Society (ICCS) criteria, desmopressin treatment failure, and persistent storage-phase LUTSs were included. Patients received mirabegron 25\u201350 mg daily (group A, n = 33) or anticholinergic therapy (group B, n = 32). The primary outcome was categorical treatment response (complete \u226575%, partial 50\u201374%, minimal 25\u201349%, failure &lt;25%). Secondary outcomes included nocturia, urgency, micturition frequency, incontinence episodes, International Prostate Symptom Score (IPSS), quality of life, and adverse events. Analyses used independent t tests, chi-square\/Fisher exact tests, paired t tests, and analysis of covariance. Results: Baseline characteristics were comparable between groups. Childhood nonmonosymptomatic enuresis phenotype was prevalent in 86.2% of patients, with reduced functional bladder capacity documented in 86.2%. Mirabegron achieved higher overall clinical benefit (\u226550% improvement) than anticholinergics (78.8% vs. 56.3%, p = 0.042) and higher complete response rates (24.2% vs. 6.3%, p = 0.044). Symptom reductions consistently favored mirabegron: nocturia 51% vs. 38% (p = 0.031), urgency 48% vs. 36% (p = 0.024), micturition frequency 37% vs. 26% (p = 0.018), and quality of life improvement 58% vs. 38% (p = 0.009). Safety profiles were comparable with no serious adverse events and similar treatment persistence (90.9% vs. 87.5%, p = 0.642). Conclusion: Pending prospective confirmation, mirabegron provides superior efficacy with comparable safety versus anticholinergic therapy in male adults with persistent LUTS after desmopressin-refractory childhood PNE, supporting \u03b23-adrenergic agonist therapy as a promising option for this underserved transitional population.<\/jats:p>","DOI":"10.1159\/000552829","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:01:23Z","timestamp":1781798483000},"page":"1-12","source":"Crossref","is-referenced-by-count":0,"title":["Mirabegron versus Anticholinergics for Persistent Lower Urinary Tract Symptoms in Male Adults after Childhood Primary Nocturnal Enuresis: A Retrospective Comparative Cohort Study"],"prefix":"10.1159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-7700","authenticated-orcid":false,"given":"Cuma","family":"Aytekin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-4920","authenticated-orcid":false,"given":"Mert","family":"Basaranoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Turhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdem","family":"Akbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erim","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S323926"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410x.2003.04612.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/00042307-200307000-00011"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpurol.2022.07.033"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.08.088"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-014-2751-5"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpurol.2016.05.029"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0495"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.05.062"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13498"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.09.012"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.10.019"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018802"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.03.020"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.01.037"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-018-0390-z"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001440"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027469"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2015.01.002"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1159\/000445808"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-016-1908-1"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.030"}],"container-title":["Urologia Internationalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000552829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:01:01Z","timestamp":1785772861000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000552829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1159\/000552829","archive":["Portico"],"relation":{},"ISSN":["0042-1138","1423-0399"],"issn-type":[{"value":"0042-1138","type":"print"},{"value":"1423-0399","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}